Cargando…
Follow-up Data of Rituximab as Adjuvant Therapy in Pemphigus
Autores principales: | Khopkar, Uday S, Chadha, Akansha Anil, Nitya, M.S.N., Lahoria, Vikram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724323/ https://www.ncbi.nlm.nih.gov/pubmed/29263549 http://dx.doi.org/10.4103/ijd.IJD_303_17 |
Ejemplares similares
-
Quantitative Estimation of Antidesmoglein Autoantibodies by ELISA in Pemphigus Patients and its Correlation with Disease Activity
por: Korgaonkar, Seema A, et al.
Publicado: (2021) -
Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis
por: Agarwal, Ashwin, et al.
Publicado: (2018) -
Extragenital lichen sclerosus et atrophicus co-exististing with pemphigus vulgaris
por: Desai, Chirag, et al.
Publicado: (2017) -
Rituximab therapy improves recalcitrant Pemphigus vulgaris
por: Noormohammadpour, Pedram, et al.
Publicado: (2015) -
Rituximab Therapy for Treatment of Pemphigus in Southeast Asians
por: Kanokrungsee, Silada, et al.
Publicado: (2021)